GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Operating Margin %

PLx Pharma (FRA:1D5A) Operating Margin % : -2,806.92% (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. PLx Pharma's Operating Income for the three months ended in Sep. 2022 was €-10.95 Mil. PLx Pharma's Revenue for the three months ended in Sep. 2022 was €0.39 Mil. Therefore, PLx Pharma's Operating Margin % for the quarter that ended in Sep. 2022 was -2,806.92%.

The historical rank and industry rank for PLx Pharma's Operating Margin % or its related term are showing as below:


FRA:1D5A's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.1
* Ranked among companies with meaningful Operating Margin % only.

PLx Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

PLx Pharma's Operating Income for the three months ended in Sep. 2022 was €-10.95 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2022 was €-59.68 Mil.


PLx Pharma Operating Margin % Historical Data

The historical data trend for PLx Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Operating Margin % Chart

PLx Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,740.58 -1,455.44 -2,511.20 -44,252.00 -496.96

PLx Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -149.06 -1,309.72 -873.72 -3,009.41 -2,806.92

Competitive Comparison of PLx Pharma's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where PLx Pharma's Operating Margin % falls into.



PLx Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

PLx Pharma's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-36.099 / 7.264
=-496.96 %

PLx Pharma's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=-10.947 / 0.39
=-2,806.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PLx Pharma  (FRA:1D5A) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


PLx Pharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma (FRA:1D5A) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines